Kawasaki disease nursing: assessment, diagnosis, and care

Kawasaki disease is a febrile vasculitis of childhood that can destroy coronary arteries in a matter of days. Without treatment, 15–25% of affected children develop coronary artery aneurysms; with timely intravenous immunoglobulin (IVIG), that rate drops below 5%. For nursing students, Kawasaki disease is high-stakes in two directions: recognizing it early (the diagnosis is clinical, with no confirmatory test), and understanding its treatment (which includes aspirin in a child — one of the most-tested NCLEX pharmacology traps in pediatrics).

This reference covers the full picture: pathophysiology, diagnostic criteria, clinical phases, coronary complications, medical management, nursing priorities, and NCLEX differentiation.

For the broader pediatric nursing framework, see pediatric nursing reference. For systemic vasculitis context, including how Kawasaki disease fits into vessel-size classification, see vasculitis nursing.

Pathophysiology and epidemiology

The etiology of Kawasaki disease remains unknown after more than five decades of study. The current consensus is that it represents an immune-mediated response to an unidentified infectious trigger — possibly a respiratory pathogen — in genetically susceptible children. The result is systemic vasculitis primarily targeting medium-sized arteries, with the coronary arteries at greatest risk because of their anatomy and flow characteristics.

The inflammatory cascade activates endothelial cells and damages the vessel wall from within, causing edema, weakening of the tunica media, and progressive arterial dilation. Without treatment, this process leads to aneurysm formation. With IVIG, the inflammatory response is blunted within 24–48 hours in most children.

Epidemiologically, Kawasaki disease occurs worldwide but is most prevalent in Japan, where the incidence is approximately 330 per 100,000 children under age 5 — roughly 30 times higher than in the United States. In the US, incidence is approximately 25 per 100,000 children under age 5. Japanese, Korean, and East Asian ancestry confers the highest genetic risk. Males are affected 1.5 times more often than females. Cases cluster in winter and spring, consistent with a seasonal infectious trigger. Children under 6 months and over 5 years have lower incidence but higher rates of coronary complications, partly because diagnosis is often delayed in atypical presentations.

Kawasaki disease is now the leading cause of acquired heart disease in children in developed countries, having surpassed rheumatic fever.

Diagnostic criteria

Kawasaki disease is a clinical diagnosis. There is no confirmatory lab test or pathognomonic finding. The American Heart Association (AHA) criteria require fever of ≥5 days plus at least four of five principal clinical features. The mnemonic CRASH covers the five features:

The fever is the principal criterion. A child who has had fever for fewer than 5 days cannot meet full Kawasaki criteria — but may meet criteria for incomplete Kawasaki disease (see below).

Incomplete (atypical) Kawasaki disease is diagnosed when a child has fever ≥5 days plus 2–3 principal criteria, with supportive laboratory and echocardiographic findings. Infants under 6 months are at especially high risk for incomplete presentation and coronary complications; they should be evaluated for Kawasaki disease after 7 days of unexplained fever even without classic features. Incomplete Kawasaki disease carries the same coronary risk as classic Kawasaki disease and is treated identically.

Key distinguishing features for NCLEX:

• Conjunctivitis is bilateral and nonpurulent (purulent discharge suggests bacterial etiology, not Kawasaki)
• Lymphadenopathy is unilateral and cervical (bilateral or generalized lymphadenopathy suggests other diagnoses)
• Rash is never vesicular (vesicles point to varicella, HSV, or Stevens-Johnson syndrome)
• Fever does not respond to antipyretics as expected — it persists despite appropriate acetaminophen dosing

Clinical phases

Kawasaki disease progresses through three defined phases. Nursing priorities shift with each phase.

Nursing note on the subacute phase: The combination of thrombocytosis and coronary aneurysms during weeks 2–4 is the period of highest risk for myocardial infarction. Children who have developed large aneurysms can present with myocardial infarction without warning. Antiplatelet therapy with low-dose aspirin during this phase is not optional.

Irritability is a defining feature of the acute phase and often the most distressing symptom for families. It is more intense and prolonged than typical fever-related fussiness and is caused by meningeal inflammation (aseptic meningitis occurs in about one-third of children). Nurses should assess and document irritability as a clinical sign, not just a behavioral complaint.

Complications

Coronary artery aneurysm

Coronary artery aneurysm (CAA) is the defining complication of Kawasaki disease and the reason for the urgency of IVIG therapy. Without treatment, 15–25% of children develop CAAs. With timely IVIG (within 10 days of fever onset), the rate drops to below 5%.

The left anterior descending (LAD) and left main coronary arteries are most commonly involved, followed by the right coronary artery (RCA). The posterior descending artery is less frequently affected.

Aneurysm classification by Z-score (coronary artery diameter standardized for body surface area, per AHA 2017 Scientific Statement):

Giant aneurysms (Z-score ≥10, absolute diameter >8 mm) carry the most significant long-term burden. They rarely regress and predispose to thrombosis, stenosis, and myocardial infarction even decades after the acute illness. Children with giant aneurysms require anticoagulation in addition to antiplatelet therapy, and they remain at cardiac risk throughout adulthood.

Regression: Small and medium aneurysms may regress (reduce to normal size) over months to years, particularly small aneurysms in children who were treated early. However, even regressed aneurysms may have functionally abnormal vessel walls with reduced vasodilatory capacity.

Other complications

• Myocardial dysfunction: Myocarditis occurs in approximately 50% of children during the acute phase and usually resolves. Pericardial effusion is common but rarely hemodynamically significant.
• Mitral regurgitation: Occurs in a subset of children during the acute phase; most cases resolve.
• Aseptic meningitis: Roughly one-third of children; causes the pronounced irritability characteristic of the disease.
• Sterile pyuria: Urethritis-related pyuria without bacteriuria is seen on urinalysis; it does not indicate urinary tract infection.
• Hydrops of the gallbladder: Common incidental finding; usually resolves without intervention.

Medical management

IVIG: the primary intervention

IVIG at 2 g/kg as a single infusion is the cornerstone of Kawasaki disease treatment. It must be given within 10 days of fever onset to prevent coronary artery aneurysms; administration within the first 7–9 days shows the greatest benefit.

The mechanism is not fully understood but likely involves modulation of inflammatory cytokine cascades, Fc receptor blockade, and complement inhibition. The clinical response is usually dramatic: fever breaks, irritability improves, and inflammatory markers fall within 24–48 hours in 85–90% of children.

IVIG-resistant Kawasaki disease (persistent or recrudescent fever >36 hours after IVIG infusion) occurs in approximately 10–15% of children. Management options include a second dose of IVIG (2 g/kg), high-dose corticosteroids (methylprednisolone IV or prednisolone orally), and in refractory cases, biologic agents such as infliximab (anti-TNF-α) or cyclosporine. IVIG resistance is associated with higher risk of coronary complications.

Aspirin: dual-dose regimen

Aspirin in Kawasaki disease is used at two very different doses for two different purposes:

The Reye syndrome exception — the NCLEX trap: Aspirin is normally contraindicated in children with viral illness because of the risk of Reye syndrome (a rare but serious condition causing acute liver failure and encephalopathy). This principle is tested extensively on NCLEX, and students are trained to select “hold aspirin” when a child has a febrile viral illness. Kawasaki disease is the explicit exception. Aspirin is not merely permitted in Kawasaki disease — it is the standard of care and must be given. An NCLEX question that asks about aspirin and a child with Kawasaki disease requires the answer “administer as prescribed,” not “hold and notify.”

For a broader review of aspirin and salicylate pharmacology, see drug classifications nursing. For cardiac medication management including anticoagulants used in giant aneurysm management, see cardiovascular medications nursing.

Echocardiogram schedule

Echocardiography is required at diagnosis (baseline), at 2 weeks, and at 6–8 weeks. Children with coronary abnormalities require additional follow-up based on Z-score classification, potentially extending to annual or biannual echocardiograms for life.

See heart failure nursing for cardiac monitoring framework and myocardial dysfunction assessment.

Nursing care

Nursing management of Kawasaki disease spans the full hospitalization and extends into a complex discharge teaching encounter. Priorities are organized below by clinical domain.

Fever management

Continuous temperature monitoring — minimum every 4 hours, more frequently in the acute phase — is essential. Document each reading with time and antipyretic administration. The pattern of fever response (or lack thereof) is clinically significant: fever that fails to break with acetaminophen supports the Kawasaki diagnosis. After IVIG infusion, document time to fever resolution; persistent or recurrent fever triggers IVIG-resistance evaluation.

For age-appropriate temperature norms and fever management principles, see vital signs by age.

Cardiac monitoring

Continuous cardiac monitoring is standard during hospitalization. Nursing assessment priorities:

• Heart rate: tachycardia beyond fever-appropriate range suggests myocarditis or pericardial effusion
• New murmur: may indicate mitral regurgitation
• Muffled heart sounds or pulsus paradoxus: suggest pericardial effusion with tamponade
• Signs of poor perfusion (poor capillary refill, altered mental status, cool extremities): medical emergency — summon the team immediately

Document all cardiorespiratory findings systematically. Children with known or suspected coronary involvement should be on telemetry.

For cardiac complication framework, see heart failure nursing.

IVIG infusion management

IVIG infusion over a large pediatric weight (2 g/kg) delivers a significant fluid volume, which may cause volume overload in small infants. Key nursing actions:

• Pre-infusion baseline: vital signs, weight, IV access patency
• Infuse at prescribed rate — typically starting slowly (e.g., 0.5–1 mL/kg/hour) and titrating up based on tolerance
• Monitor for infusion reactions throughout: flushing, chills, tachycardia, hypotension, nausea, back pain
• Stop infusion immediately for signs of anaphylaxis; have epinephrine, diphenhydramine, and resuscitation equipment available
• Post-infusion: reassess vital signs and fever status; document fever response time

Comfort and oral care

The oral manifestations of Kawasaki disease — cracked lips, strawberry tongue, oropharyngeal erythema — cause significant pain and feeding refusal, particularly in infants.

• Apply petroleum jelly to cracked lips
• Oral hygiene with soft-bristle toothbrush; avoid alcohol-based mouthwash
• Offer soft, cool foods and appropriate fluids for age; avoid acidic or salty foods during the acute phase
• Assess pain at each interaction; age-appropriate pain tools (FLACC for under age 3, FACES or numeric scale for older children)

Skin care: the rash and subsequent desquamation require gentle handling. Use mild, fragrance-free products; keep skin moisturized during the peeling phase.

Irritability management and family support

Kawasaki disease produces profound irritability that is distressing to families and physically exhausting for staff. Parents who have managed the child’s illness at home for days before admission are often frightened, sleep-deprived, and confused about why their child has not been diagnosed sooner (the diagnostic delay in atypical presentations is common).

• Minimize unnecessary stimulation: cluster care, dim lighting, maintain routine as much as possible
• Involve parents in comfort measures — familiar caregivers significantly reduce distress
• Provide clear, honest education about the diagnosis, the role of IVIG, and the coronary risk; avoid minimizing while also avoiding catastrophizing
• Acknowledge diagnostic uncertainty without undermining trust — families often feel dismissed during the pre-diagnosis period

NCLEX differentiation: Kawasaki vs similar conditions

MIS-C nursing note: Multisystem inflammatory syndrome in children (MIS-C), which emerged during the COVID-19 pandemic, shares many features with Kawasaki disease — fever, rash, conjunctivitis, oral changes, and coronary artery involvement. Key distinctions: MIS-C typically affects older children (school age rather than toddlers), has prominent gastrointestinal symptoms (vomiting, abdominal pain, diarrhea), shows positive COVID-19 serology in most cases, and often presents with a more severe shock-like picture. Treatment protocols are similar (IVIG ± aspirin ± steroids), which reflects the overlapping inflammatory pathophysiology. For COVID-19 nursing context including MIS-C, see the site’s COVID-19 nursing reference.

Discharge teaching

Discharge from acute Kawasaki hospitalization does not end the nursing encounter — the post-discharge teaching conversation is complex and involves medication adherence, safety monitoring, and long-term cardiac surveillance.

Aspirin adherence: Low-dose aspirin (3–5 mg/kg/day) must continue for at least 6–8 weeks. Parents must understand: do not stop aspirin without physician clearance after the follow-up echocardiogram. If coronary aneurysms are present, aspirin may continue indefinitely. Instruct parents to store aspirin away from heat and moisture, and to administer with food to reduce gastric irritation.

Reye syndrome precautions during aspirin therapy: While Kawasaki disease requires aspirin, children on long-term aspirin are at risk for Reye syndrome if they develop varicella or influenza during the aspirin course. Parents should call the provider immediately if the child develops chickenpox or is exposed to influenza so that aspirin management can be reviewed. The flu vaccine is recommended for aspirin-treated children.

Live vaccine delay: IVIG suppresses the immune response to live attenuated vaccines for approximately 11 months. The MMR (measles-mumps-rubella) and varicella vaccines must be delayed for 11 months after IVIG administration. Parents should notify the pediatrician and inform the primary care provider of the IVIG date so the vaccine schedule can be adjusted.

Echocardiogram follow-up: A follow-up echocardiogram is scheduled at 2 weeks and 6–8 weeks. These appointments are not optional — they confirm whether coronary aneurysms developed. Parents should not miss them even if the child appears entirely well.

Signs to return immediately:

• New fever (possible IVIG resistance or second episode; rare recurrence rate of 1–3%)
• Chest pain, shortness of breath, or sudden pallor/diaphoresis (myocardial ischemia)
• Child appears suddenly ill or deteriorates unexpectedly

For the croup-vs-epiglottitis framework useful when counseling parents about fever and airway symptoms in toddlers, see croup nursing and epiglottitis nursing.

NCLEX tips

• Fever duration is the gating criterion. A child with 4 days of fever plus all five clinical features does not yet meet full diagnostic criteria. Fever must be ≥5 days. (Incomplete Kawasaki can be considered earlier with supportive findings, but the classic criteria require 5 days.)

• Aspirin in Kawasaki disease is the expected answer on NCLEX — not a contraindication. When the question stem says “Kawasaki disease” and asks about aspirin, the answer is to administer it. The Reye syndrome rule applies to viral illness in general, not to Kawasaki disease specifically.

• IVIG timing matters. The single most important intervention is IVIG within 10 days of fever onset. Questions testing priority of care — “which order should the nurse carry out first” — IVIG takes precedence.

• Conjunctivitis in Kawasaki disease is bilateral and nonpurulent. If there is purulent discharge, this is not consistent with Kawasaki disease; reconsider the diagnosis.

• Lymphadenopathy is unilateral and cervical. This distinguishes Kawasaki from viral illnesses that cause bilateral or generalized adenopathy.

• Periungual desquamation is a subacute finding. A child presenting late — days 12–20 of illness — may have resolving fever but striking peeling beginning at the fingertips and toes. Recognize this as the subacute phase of Kawasaki disease.

• Thrombocytosis peaks in the subacute phase. Platelet counts can exceed 1,000,000/µL. This dramatically increases thrombosis risk in the setting of coronary aneurysms — reinforcing why low-dose antiplatelet aspirin cannot be stopped early.

• The most serious long-term complication is coronary artery aneurysm. NCLEX questions about complications of Kawasaki disease nearly always expect this answer. Without treatment, 15–25% develop CAA; with IVIG, under 5%.

• Giant aneurysm = highest risk category. Z-score ≥10 or diameter >8 mm. Requires anticoagulation (not just antiplatelet therapy) because of thrombosis and MI risk.

• Echocardiogram is required at diagnosis, 2 weeks, and 6–8 weeks. Repeating the echocardiogram is not optional even if the child looks clinically well.

• Live vaccines (MMR, varicella) are delayed 11 months after IVIG. This is a straightforward NCLEX immunization question. The answer: delay, do not skip permanently.

• MIS-C vs Kawasaki: On NCLEX questions, the key differentiating features are age (MIS-C = older children), COVID-19 exposure or serology, and prominent GI symptoms (vomiting, abdominal pain). Treatment protocols overlap significantly.

• Sterile pyuria on urinalysis is a supportive finding in Kawasaki disease. It represents urethritis, not UTI. Urine culture will be negative. Do not initiate antibiotics for sterile pyuria in a child with suspected Kawasaki disease.

• IVIG-resistance (10–15% of cases): Fever persists or recurs >36 hours after infusion. Second-line treatment is a second IVIG dose or IV methylprednisolone, not antibiotics. If an NCLEX question describes a child whose fever returns the day after IVIG for Kawasaki disease, IVIG resistance is the expected answer.

• Coronary artery aneurysm classification uses Z-scores, not absolute size alone (except for the giant aneurysm cutoff of >8 mm, which appears frequently in questions). Z-score adjusts for body surface area — relevant because small children have small coronary arteries and a 4 mm aneurysm means something very different in a toddler vs. an adolescent.